Mark your calendars: Eli Lilly will come before the FDA’s advisory committee to discuss Alzheimer’s disease medicine donanemab June 10. The Peripheral and Central Nervous System Drugs Advisory ...

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction in early Alzheimer's disease, the ...

Before this announcement, a regulatory decision was expected in the first quarter of 2024. The Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS ...

While the first-mover advantage is often critical in the realm of drug launches, Eli Lilly is often happy to split the pie with its peers. That’s proven true in obesity, where the company recently ...

The U.S. Food and Drug Administration has delayed action for the promising Alzheimer’s treatment donanemab, the drug manufacturer said on Friday. Eli Lilly said the FDA would wait on ruling about ...

(CNN) — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by ...

Editor’s Note: “Dr. Sanjay Gupta Reports: The Last Alzheimer’s Patient” airs at 8 p.m. ET Sunday, July 7, on CNN. The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal ...